EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparison of a Novel Liquid Embolic System with Commonly Used Embolic Agents in the Endovascular Treatment of Intracranial Dural Arteriovenous Fistulas: A Single-Center Experience

Zarko Nedeljkovic iD, Ivan Vukasinovic iD, Masa Petrovic iD, Aleksandra Nedeljkovic iD, Tijana Nastasovic iD, Vladimir Bascarevic, Mirko Micovic iD, Mihailo Milicevic iD, Marina Milic iD, Nemanja Jovanovic iD, Aleksandar Stanimirovic, Vuk Scepanovic und 1 weitere

Journal of Clinical Medicine · 02.10.2024 · 13 (19) · 5899

DOI: 10.3390/jcm13195899 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 02.10.2024. Verfasst von Zarko Nedeljkovic und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Neurosurgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Endovascular embolization is an effective treatment option for cerebral arteriovenous malformation (AVM) and dural arteriovenous fistulas (DAVFs). The objective of this study was to assess the safety and efficacy of MenoxTM in patients with cranial dural arteriovenous fistulas.

Methods

From January 2021 to January 2023, 19 patients with intracranial DAVFs underwent embolization procedures. All patients were treated by embolization with MenoxTM or/and in combination with other embolization products such as Onyx (Covidien, Irvine, California), PHIL (MicroVention, Tustin, California), and Squid (Balt Extrusion, Montmorency, France). Treatment approaches were selected depending on the anatomical location of the fistula. Patients were monitored and followed-up for 12 months.

Results

The patients’ mean age was 56.26 ± 16.49 years. Of these 19 patients, 58% (n = 11) were treated with the MenoxTM liquid embolizing agent (LEA) alone or in combination with different LEAs, while n = 7 were treated with other LEAs and 1 patient was treated solely with coils. Complete occlusion of DAVFs with MenoxTM and other agents was evident in 68.4% (n = 13/19) of patients. Complete occlusion (100%) was observed in the sinus rectus, transverse sinus, and diploic veins of the orbital roof, while complete occlusion was observed in 50% of falcotentorial patients and 60% of superior sagittal sinus patients. The lowest rate of complete fistula obliteration was observed in the dural carotid cavernous fistula (CCF) group (25%). An intra-procedural adverse event occurred in one patient. No other post-procedural adverse events were noted. Furthermore, in patients treated with MenoxTM, total occlusion was achieved in 72.7% (n = 8) of patients, whereas the non-MenoxTM group had 62.5% (n = 5) of patients with 100% occlusion and 37.5% (n = 3) of patients with subtotal occlusion.

Conclusions

Outcomes using MenoxTM alone and in combination with other agents were effective, and it is safe for the treatment of dural arteriovenous fistulas.

Schlagwörter

Stichwörter der Autor:innen

carotid cavernous fistuladural arteriovenous fistulaembolizationendovascular proceduresliquid embolic agent

Autor:innen und Institutionen

  • Clinic for Neurosurgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
  • Center for Radiology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
  • Institute for Cardiovascular Diseases "Dedinje", Heroja Milana Tepica 1, 11000 Belgrade, Serbia.
  • Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
  • Department of Anesthesiology and Resuscitation on Neurosurgery Clinic, University Clinical Center of Serbia, 11000 Belgrade, Serbia.

ORCID-Profile: Zarko Nedeljkovic, Ivan Vukasinovic, Masa Petrovic, Aleksandra Nedeljkovic, Tijana Nastasovic, Mirko Micovic, Mihailo Milicevic, Marina Milic, Nemanja Jovanovic

Zitieren

APA

Nedeljkovic, Z., Vukasinovic, I., Petrovic, M., Nedeljkovic, A., Nastasovic, T., Bascarevic, V., Micovic, M., Milicevic, M., Milic, M., Jovanovic, N., Stanimirovic, A., Scepanovic, V., & Grujicic, D. (2024). Comparison of a Novel Liquid Embolic System with Commonly Used Embolic Agents in the Endovascular Treatment of Intracranial Dural Arteriovenous Fistulas: A Single-Center Experience. Journal of Clinical Medicine, 13(19), 5899. https://doi.org/10.3390/jcm13195899

Vancouver

Nedeljkovic Z, Vukasinovic I, Petrovic M, Nedeljkovic A, Nastasovic T, Bascarevic V, et al. Comparison of a Novel Liquid Embolic System with Commonly Used Embolic Agents in the Endovascular Treatment of Intracranial Dural Arteriovenous Fistulas: A Single-Center Experience. Journal of Clinical Medicine. 2024;13(19):5899. doi:10.3390/jcm13195899

BibTeX
@article{Nedeljkovic2024,
  author = {Nedeljkovic, Zarko and Vukasinovic, Ivan and Petrovic, Masa and Nedeljkovic, Aleksandra and Nastasovic, Tijana and Bascarevic, Vladimir and Micovic, Mirko and Milicevic, Mihailo and Milic, Marina and Jovanovic, Nemanja and Stanimirovic, Aleksandar and Scepanovic, Vuk and Grujicic, Danica},
  title = {Comparison of a Novel Liquid Embolic System with Commonly Used Embolic Agents in the Endovascular Treatment of Intracranial Dural Arteriovenous Fistulas: A Single-Center Experience},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {19},
  pages = {5899},
  doi = {10.3390/jcm13195899}
}
Kostenlos starten →